The Immutep (ASX:IMM) share price is up 6% today

Immutep has received all the approvals it needs to begin its latest trial in the United States.

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Immutep Ltd (ASX: IMM) are soaring today following news of its latest drug trial. Currently, the Immutep share price is trading at 56 cents, 5.6% higher than its previous close.

The biotechnology company has received approval from both the United States Food and Drug Association (FDA) and Institutional Review Board (IRB) to begin the trial.

Let's take a closer look at today's news from Immutep.

New trial gets US approval

Immutep can now begin a phase IIb trial, combining its lead product candidate, eftilagimod alpha (efti), with MSD's immunotherapy treatment, Keytruda (pembrolizumab).

The company — which develops immunotherapy treatments for cancer and autoimmune disease — is focussing on Efti, an antigen-presenting cell activator.

Immutep advised that the TACTI-003 trial will be a randomised, controlled clinical study. It aims to find if efti and pembrolizumab can be combined to treat head and neck squamous cell carcinoma (HNSCC).

Immutep plans for the trial to involve around 154 patients. It hopes it will take place in Australia and Europe, as well as the United States.

The trial is pending approval from authorities and ethics committees in Australia and Europe.

Immutep expects patient recruitment for the trial to begin in the United States in the current quarter, with Australian and European sites to follow.

Commentary from management

Immutep chief scientific officer and chief medical officer Frédéric Triebel said:

We are delighted to start our new TACTI-003 trial in 1st line HNSCC patients to evaluate efti in combination with pembrolizumab vs pembrolizumab monotherapy.

Results we reported from this therapeutic combination earlier in June at [the American Society of Clinical Oncology] in the 2nd line setting were robust, with sustained and durable responses. We look forward to deepening these results with a larger group of 1 st line HNSCC patients in TACTI-003.

Immutep share price snapshot

2021 has been a good year so far for the Immutep share price on the ASX.

It's currently 34% higher than it was at the start of the year, and has gained 232% since this time last year.

The company has a market capitalisation of around $407 million, with approximately 648 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX 200 stock crashing 30% today?

What's going with this stock? Let's find out why its shares are deep in the red.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

Buying the dip: $10,000 invested in Pro Medicus shares on 7 April is now worth…

This healthcare stock has boomed over the past month. 

Read more »

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »